• Mehdi Moghaddasi, Mansoureh Mamarabadi, Nafiseh Mohebi, Hadie Razjouyan, and Mahbubeh Aghaei.
• Department of Neurology, Rasool Akram Hospital, Tehran University of Medical Sciences, Tehran, Iran.
• Clin Neurol Neurosurg. 2013 Sep 1; 115 (9): 1802-5.

BackgroundRecently, homocysteine (Hcy), folate, and vitamin B12 have been proposed to have several roles on MS pathogenesis.ObjectiveWe performed this study to determine the role of serum levels of Hcy, vitamin B12, and folate in patients with relapsing remitting MS (RRMS) and compared them with healthy controls.MethodsWe recruited 75 RRMS patients and 75 subjects as controls with the same age and sex. Homocysteine was measured using fluorimetric high-performance liquid chromatography. Plasma folate and vitamin B12 levels were measured through ion-capture method.ResultsMean plasma levels of vitamin B12, folate, and Hcy in cases were 342.64 ± 210.66 pg/ml, 9.74 ± 4.77 ng/ml, and 22.73 ± 11.63 μM/L, respectively, which showed significant difference in comparison with the controls. In addition, there were significant correlations between mean serum Hcy levels and duration of disease (r=0.2, p=0.05) and treatment with interferon (r=0.21, p=0.01). In cases, Hcy level was higher among those on β interferon (24.56 ± 11.87 vs. 19.71 ± 10.75, p=0.01).ConclusionsWe concluded that serum levels of vitamin B12 and folate decreased in RRMS patients, but Hcy levels increased significantly. It seems necessary to conduct prospective trials to determine whether the treatment with supplements and correct biomarker levels in the early stage of the disease can change the course of the disease. We recommend regular checking of the serum level of Hcy in patients who use disease-modifying drugs.Copyright © 2013 Elsevier B.V. All rights reserved.

24 keywords...

hide…